Patents by Inventor George P. Livi
George P. Livi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6909029Abstract: This invention relates to methods for producing a transgenic C. elegans that expresses a human 7TMR pan-neuronally, such that said transgenic C. elegans exhibits a known phenotype. These transgenic C. elegans can be used in a variety of ways, including, but not limited to: (1) screening and identifying substances that bind to and activate particular human 7TMRs; (2) screening for substances that antagonize human 7TMR activation; (3) identifying human 7TMRs that may respond to particular substances; and (4) evaluating the specificity and efficacy of substances on human 7TMR activation.Type: GrantFiled: September 26, 2001Date of Patent: June 21, 2005Assignee: SmithKline Beecham CorporationInventors: George P. Livi, Christopher Shelton
-
Publication number: 20040231008Abstract: This invention relates to methods for producing a transgenic C. elegans that expresses a human 7TMR pan-neuronally, such that said transgenic C. elegans exhibits a known phenotype. These transgenic C. elegans can be used in a variety of ways, including, but not limited to: (1) screening and identifying substances that bind to and activate particular human 7TMRs; (2) screening for substances that antagonize human 7TMR activation; (3) identifying human 7TMRs that may respond to particular substances; and (4) evaluating the specificity and efficacy of substances on human 7TMR activation.Type: ApplicationFiled: June 18, 2004Publication date: November 18, 2004Applicant: SmithKline Beecham CorporationInventors: George P. Livi, Christopher Shelton
-
Publication number: 20030082743Abstract: Human EDG-1c polypeptidees and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Human EDG-1c is identified as a selective receptor for sphingosine-1-phosphate (“S-1-P”) and for di-hydro S-1-P.Type: ApplicationFiled: January 12, 2001Publication date: May 1, 2003Inventors: Derk J. Bergsma, Winnie Chan, Jonathan K. Chambers, Randall K. Johnson, Nassirah Khandoudi, George P. Livi, Phillipe Robert, Jeffrey M. Stadel, Pamela Joy Jensen, Shelagh Wilson
-
Publication number: 20020124275Abstract: This invention relates to methods for producing a transgenic C. elegans that expresses a human 7TMR pan-neuronally, such that said transgenic C. elegans exhibits a known phenotype. These transgenic C. elegans can be used in a variety of ways, including, but not limited to: (1) screening and identifying substances that bind to and activate particular human 7TMRs; (2) screening for substances that antagonize human 7TMR activation; (3) identifying human 7TMRs that may respond to particular substances; and (4) evaluating the specificity and efficacy of substances on human 7TMR activation.Type: ApplicationFiled: September 26, 2001Publication date: September 5, 2002Inventors: George P. Livi, Christopher Shelton
-
Publication number: 20020068351Abstract: Isolated cDNA clones from human brain (frontal cortex) cDNA libraries that encode a unique subtype of the low Km, cAMP-specific phosphodiesterases (PDE IVs) are disclosed. Analysis of the distribution of hPDE IVB mRNA expression in various human tissues using a nonconserved fragment of the cDNA as a probe revealed a restricted pattern of expression, with an ˜4-kb mRNA detected in brain, heart, lung and skeletal muscle and not in placenta, liver, kidney or pancreas. Furthermore, an additional ˜5-kb hPDE IVB− related mRNA species was detected in brain tissue. Expression of hPDE IVB in a genetically-engineered PDE-deficient strain of the yeast Saccharomyces cerevisiae resulted in the overproduction of cAMP PDE activity which displayed the expected kinetic characteristics for a PDE IV: 1) low Km (4.3 &mgr;M) for cAMP, 2) high Km (>3 mM) for cGMP, and 3) sensitivity to rolipram (Ki=0.085 &mgr;M), a selective inhibitor of PDE IV.Type: ApplicationFiled: September 5, 2001Publication date: June 6, 2002Applicant: SmithKline Beecham CorporationInventors: George P. Livi, Megan M. McLaughlin, Theodore J. Torphy
-
Patent number: 6306583Abstract: Isolated cDNA clones from human brain (frontal cortex) cDNA libraries that encode a unique subtype of the low Km, cAMP-specific phosphodiesterases (PDE IVs) are disclosed. Analysis of the distribution of hPDE IVB mRNA expression in various human tissues using a nonconserved fragment of the cDNA as a probe revealed a restricted pattern of expression, with an ˜4-kb mRNA detected in brain, heart, lung and skeletal muscle and not in placenta, liver, kidney or pancreas. Furthermore, an additional ˜5-kb hPDE IVB-related mRNA species was detected in brain tissue. Expression of hPDE IVB in a genetically-engineered PDE-deficient strain of the yeast Saccharomym cerevisiae resulted in the overproduction of cAMP PDE activity which displayed the expected kinetic characteristics for a PDE IV: 1) low Km (4.3 &mgr;M) for cAMP, 2) high Km (>3 mM) for cGMP, and 3) sensitivity to rolipram (Ki=0.085 &mgr;M), a selective inhibitor of PDE IV.Type: GrantFiled: May 22, 1995Date of Patent: October 23, 2001Assignee: SmithKline Beecham CorporationInventors: George P. Livi, Megan M. McLaughlin, Theodore J. Torphy
-
Patent number: 6159716Abstract: hYAK1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed.Type: GrantFiled: July 9, 1999Date of Patent: December 12, 2000Assignee: SmithKline Beecham CorporationInventors: Caretha L. Creasy, George P. Livi, Damien J. Dunnington, Usman Shabon
-
Patent number: 6150150Abstract: Isolated cDNA clones from human brain (frontal cortex) cDNA libraries that encode a unique subtype of the low K.sub.m, cAMP-specific phosphodiesterases (PDE IVs) are disclosed. Analysis of the distribution of hPDE IV.sub.B mRNA expression in various human tissues using a nonconserved fragment of the cDNA as a probe revealed a restricted pattern of expression, with an .about.4-kb mRNA detected in brain, heart, lung and skeletal muscle and not in placenta, liver, kidney or pancreas. Furthermore, an additional .about.5-kb hPDE IV.sub.B.sup.- related mRNA species was detected in brain tissue. Expression of hPDE IV.sub.B in a genetically-engineered PDE-deficient strain of the yeast Saccharomyces cerevisiae resulted in the overproduction of cAMP PDE activity which displayed the expected kinetic characteristics for a PDE IV: 1) low K.sub.m (4.3 .mu.M) for cAMP, 2) high K.sub.m (>3 mM) for cGMP, and 3) sensitivity to rolipram (K.sub.i =0.085 .mu.M), a selective inhibitor of PDE IV. Recombinant hPDE IV.sub.Type: GrantFiled: November 16, 1998Date of Patent: November 21, 2000Assignee: SmithKline Beecham CorporationInventors: George P. Livi, Megan M. McLaughlin, Theodore J. Torphy
-
Patent number: 5972606Abstract: hYAK1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed.Type: GrantFiled: February 19, 1997Date of Patent: October 26, 1999Assignee: SmithKline Beecham CorporationInventors: Caretha L. Creasy, George P. Livi, Damien J. Dunnington, Usman Shabon
-
Patent number: 5932477Abstract: Isolated cDNA clones from human brain (frontal cortex) cDNA libraries that encode a unique subtype of the low K.sub.m, cAMP-specific phosphodiesterases (PDE IVs) are disclosed. Analysis of the distribution of hPDE IV.sub.B mRNA expression in various human tissues using a nonconserved fragment of the cDNA as a probe revealed a restricted pattern of expression, with an .about.4-kb MRNA detected in brain, heart, lung and skeletal muscle and not in placenta, liver, kidney or pancreas. Furthermore, an additional .about.5-kb hPDE IV.sub.B.sup.- related mRNA species was detected in brain tissue. Expression of hPDE IV.sub.B in a genetically-engineered PDE-deficient strain of the yeast Saccharomyces cerevisiae resulted in the overproduction of cAMP PDE activity which displayed the expected kinetic characteristics for a PDE IV: 1) low K.sub.m (4.3 .mu.M) for cAMP, 2) high K.sub.m (>3 mM) for cGMP, and 3) sensitivity to rolipram (K.sub.i =0.085 .mu.M), a selective inhibitor of PDE IV. Recombinant HPDE IV.sub.Type: GrantFiled: October 2, 1997Date of Patent: August 3, 1999Assignee: SmithKline Beecham CorporationInventors: George P. Livi, Megan M. McLaughlin, Theodore J. Torphy
-
Patent number: 5817466Abstract: This invention relates to nucleic acid sequences conserved in strains of yeasts. More particularly, this invention relates to segments of the ALS1 gene of Candida albicans useful as probes and primers for the identification of yeast, particularly Candida, infections.Type: GrantFiled: June 18, 1997Date of Patent: October 6, 1998Assignee: SmithKline Beecham CorporationInventors: Lois L. Hoyer, George P. Livi, Allan R. Shatzman
-
Patent number: 5668263Abstract: This invention relates to nucleic acid sequences conserved in strains of yeasts. More particularly, this invention relates to segments of the ALSl gene of Candida albicans useful as probes and primers for the identification of yeast, particularly Candida, infections.Type: GrantFiled: December 16, 1994Date of Patent: September 16, 1997Assignee: SmithKline Beecham CorporationInventors: Lois L. Hoyer, George P. Livi, Allan R. Shatzman